
    
      1. To evaluate safety and tolerability of Hetrombopag Olamine.

        2. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions.

        3. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count
           elevation in healthy volunteers.

        4. To determine preliminary regimen for phase II study.
    
  